Table 2 The performances of the PE models in the validation set of 36 EPE, 46 LPE, 82 Preterm PE and 217 healthy participants
| Â | Group | True positive | False positive | True negative | False negative | Sensitivity | Specificity | PPV | NPV | Cutoff |
|---|---|---|---|---|---|---|---|---|---|---|
Clinical factors | EPE | 21 | 32 | 185 | 15 | 58.33% (95% CI, 42.23%-74.44%) | 85.25% (95% CI,80.54%-90%) | 39.62% (95% CI,26.45%-52.79%) | 92.5% (95% CI,88.85%-96.15%) | 0.1 |
Preterm PE | 50 | 32 | 185 | 32 | 60.98% (95% CI, 50.42%-71.53%) | 85.25% (95% CI,80.54%-90%) | 60.98% (95% CI,50.42%-71.53%) | 85.25% (95% CI,80.54%-90%) | 0.17 | |
LPE | 30 | 32 | 185 | 16 | 65.22% (95% CI, 51.45%-78.98%) | 85.25% (95% CI, 80.54%-89.97%) | 48.39% (95% CI,35.95%-60.83%) | 92.04% (95% CI,88.3%-95.78%) | 0.35 | |
Clinical factors + lab variables | EPE | 26 | 32 | 185 | 10 | 72.22% (95% CI, 57.59%-86.85%) | 85.25% (95% CI, 80.54%-89.97%) | 44.83% (95% CI,32.03%-57.63%) | 94.87% (95% CI,91.78%-97.97%) | 0.09 |
Preterm PE | 52 | 32 | 185 | 30 | 63.41% (95% CI, 52.99%-73.84%) | 85.25% (95% CI, 80.54%-89.97%) | 61.9% (95% CI,51.52%-72.29%) | 86.05% (95% CI, 81.41%-90.68%) | 0.18 | |
LPE | 32 | 32 | 185 | 14 | 69.57% (95% CI, 56.27%-82.86%) | 85.25% (95% CI, 80.54%-89.97%) | 50% (95% CI,37.75%-62.25%) | 92.96% (95% CI,89.41%-96.52%) | 0.36 |